undamentalytics Newsletter
Sign in

Pyxis Oncology, Inc. cash flow statement

In fiscal 2025, Pyxis Oncology, Inc.'s operations generated −$63.5m of cash; it spent $9,000 on capital projects, leaving free cash flow of −$63.5m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025
Cash from operations−58−64
Depreciation and amortisation35
Stock-based pay1312
Capital spending00
Free cash flow−58−64
Free cash flow after stock pay−71−75

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: KROS vs PYXSPRQR vs PYXSCTMX vs PYXS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Pyxis Oncology, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Pyxis Oncology, Inc.